[1] KOUKA M,BUENTZEL J,KAFTAN H,et al.Early mortality among patients with head and neck cancer diagnosed in Thuringia,Germany,between 1996 and 2016-apopulation-based study[J].Cancers(Basel),2022,14(13):3099.
[2] 张考,黄啸,熊思.血清外泌体LncRNA ZFAS1与老年局部中晚期不可切除食管癌患者病理特征及同步放化疗敏感性的关系研究[J].现代医学,2022,50(8):987-994.
[3] 唐媛媛,于佳妮,曾珊,等.伴吞咽困难的Ⅳa/b期食管癌患者放疗或同步放化疗期间不同营养治疗模式应用研究[J].现代医学,2022,50(11):1382-1387.
[4] LACAS B,CARMEL A,LANDAIS C,et al.Meta-analysis of chemotherapy in head and neck cancer(MACH-NC):an update on 107 randomized trials and 19,805 patients,on behalf of MACH-NC group[J].Radiother Oncol,2021,156:281-293.
[5] FORASTIERE A A,ZHANG Q,WEBER R S,et al.Long-term results of RTOG 91-11:a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer[J].J Clin Oncol,2013,31(7):845-852.
[6] LU Z,WANG J,SHU Y,et al.Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma(ORIENT-15):multicentre,randomised,double blind,phase 3 trial[J].BMJ,2022,377:e068714.
[7] VERMORKEN J B,MESIA R,RIVERA F,et al.Platinum-based chemotherapy plus cetuximab in head and neck cancer[J].N Engl J Med,2008,359(11):1116-1127.
[8] XING D,SIVA S,HANNA G G.The abscopal effect of stereotactic radiotherapy and immunotherapy:fool's gold or eldorado?[J].Clin Oncol(R Coll Radiol),2019,31(7):432-443.
[9] ROEZE S,PAVIC M,STELLAMANS K,et al.Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy:systematic review and consensus recommendations by the eortc-estro oligocare consortium[J].Lancet Oncol,2023,24(3):e121-e132.
[10] SACCO A G,CHEN R,WORDEN F P,et al.Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma:an open-label,multi-arm,non-randomised,multicentre,phase 2 trial[J].Lancet Oncol,2021,22(6):883-892.
[11] WANG Z,GOTO Y,ALLEVATO M M,et al.Disruption of the HER3-PI3K-mtor oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer[J].Nat Commun,2021,12(1):2383.
[12] PIGNON J P,BOURHIS J,DOMENGE C,et al.Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma:three Meta-analyses of updated individual data.Mach-nc collaborative group.Meta-analysis of chemotherapy on head and neck cancer[J].Lancet,2000,355(9208):949-955.
[13] PATIL V M,NORONHA V,JOSHI A,et al.A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer[J].Cancer,2019,125(18):3184-3197.
[14] QIU M Z,ZHANG Y,GUO Y,et al.Evaluation of safety of treatment with anti-epidermal growth factor receptor antibody drug conjugate MRG003 in patients with advanced solid tumors:a phase 1 nonrandomized clinical trial[J].JAMA Oncol,2022,8(7):1042-1046.
[15] SCHINKE H,SHI E,LIN Z,et al.A transcriptomic map of EGFR-induced epithelial-to-mesenchymal transition identifies prognostic and therapeutic targets for head and neck cancer[J].Mol Cancer,2022,21(1):178.
[16] QUREISHI A,RIEUNIER G,SHAH K A,et al.Radioresistant laryngeal cancers upregulate type 1 IGF receptor and exhibit increased cellular dependence on IGF and EGF signalling[J].Clin Otolaryngol,2019,44(6):1026-1036.
[17] FERRIS R L,MOSKOVITZ J,KUNNING S,et al.Phase I trial of cetuximab,radiotherapy,and ipilimumab in locally advanced head and neck cancer[J].Clin Cancer Res,2022,28(7):1335-1344.
[18] CITRON F,SEGATTO I,MUSCO L,et al.MiR-9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC[J].EMBO Mol Med,2021,13(7):e12872.
[19] COHEN E,BELL R B,BIFULCO C B,et al.The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck(HNSCC)[J].J Immunother Cancer,2019,7(1):184.
[20] POWELL S F,GOLD K A,GITAU M M,et al.Safety and efficacy of pembrolizumab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma:a phase IB study[J].J Clin Oncol,2020,38(21):2427-2437.
[21] FENG L,YIN K,ZHANG S,et al.Anti-PD-1 therapy is beneficial for the survival of patients with oral squamous cell carcinoma[J].Cancer Manag Res,2022,14:2723-2731.
[22] DOU S,LI R,HE N,et al.The immune landscape of chinese head and neck adenoid cystic carcinoma and clinical implication[J].Front Immunol,2021,12:618367.
[23] ZHANG W,YAN C,GAO X,et al.Safety and feasibility of radiotherapy plus camrelizumab for locally advanced esophageal squamous cell carcinoma[J].Oncologist,2021,26(7):e1110-e1124.
[24] YANG B,LIU T,QU Y,et al.Progresses and perspectives of anti-PD-1/PD-L1 antibody therapy in head and neck cancers[J].Front Oncol,2018,8:563.
[25] CILLO A R,KVRTEN C,TABIB T,et al.Immune landscape of viral-and carcinogen-driven head and neck cancer[J].Immunity,2020,52(1):183-199.e9.
[26] CHEN S,KRINSKY A L,WOOLAVER R A,et al.Tumor immune microenvironment in head and neck cancers[J].Mol Carcinog,2020,59(7):766-774.
[27] EGLOFF A M,UPPALURI R.Preoperative immunotherapy for head and neck cancers:state of art[J].Curr Opin Oncol,2022,34(3):185-195.
[28] MACHIELS J P,TAO Y,BURTNESS B,et al.Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma:KEYNOTE-412[J].Future Oncol,2020,16(18):1235-1243.
[29] CONCHA-BENAVENTE F,SRIVASTAVA R,FERRONE S,et al.Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells[J].Oral Oncol,2016,58:52-58.
[30] LUO X,CHEN Y,TANG H,et al.Melatonin inhibits EMT and PD-L1 expression through the ERK1/2/FOSL1 pathway and regulates anti-tumor immunity in HNSCC[J].Cancer Sci,2022,113(7):2232-2245.
[31] ZHANG W,YAN C,ZHANG T,et al.Addition of camrelizumab to docetaxel,cisplatin,and radiation therapy in patients with locally advanced esophageal squamous cell carcinoma:a phase 1B study[J].Oncoimmunology,2021,10(1):1971418.
[32] HU X,WANG J,CHU M,et al.Emerging role of ubiquitination in the regulation of PD-1/PD-L1 in cancer immunotherapy[J].Mol Ther,2021,29(3):908-919.
[33] DE MARTINO M,DAVIAUD C,VANPOUILLE-BOX C.Radiotherapy:an immune response modifier for immuno-oncology[J].Semin Immunol,2021,52:101474.
[34] CARVALHO H A,VILLAR R C.Radiotherapy and immune response:the systemic effects of a local treatment[J].Clinics(Sao Paulo),2018,73(suppl 1):e557s.
[35] HERRERA F G,RONET C,OCHOA DE OLZA M,et al.Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy[J].Cancer Discov,2022,12(1):108-133.
[36] WALLE T,KRASKE J A,LIAO B,et al.Radiotherapy orchestrates natural killer cell dependent antitumor immune responses through CXCL8[J].Sci Adv,2022,8(12):eabh4050.
[37] MOREIRA D,SAMPATH S,WON H,et al.Myeloid cell-targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell-mediated immunity[J].J Clin Invest,2021,131(2):e137001.
[38] VON WITZLEBEN A,WANG C,LABAN S,et al.Hnscc:tumour antigens and their targeting by immunotherapy[J].Cells,2020,9(9):2103.
[39] LEIDNER R,CRITTENDEN M,YOUNG K,et al.Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma[J].J Immunother Cancer,2021,9(5):e002485.
[40] WEISS J,SHETH S,DEAL A M,et al.Concurrent definitive immunoradiotherapy for patients with stage Ⅲ-Ⅳ head and neck cancer and cisplatin contraindication[J].Clin Cancer Res,2020,26(16):4260-4267.
[41] VARGO J A,MOISEENKO V,GRIMM J,et al.Head and neck tumor control probability:radiation dose-volume effects in stereotactic body radiation therapy for locally recurrent previously-irradiated head and neck cancer:report of the aapm working group[J].Int J Radiat Oncol Biol Phys,2021,110(1):137-146.
[42] HUI C,CHAU B,GAN G,et al.Overcoming resistance to immunotherapy in head and neck cancer using radiation:a review[J].Front Oncol,2021,11:592319.
[43] VARGO J A,WARD M C,CAUDELL J J,et al.A multi-institutional comparison of sbrt and imrt for definitive reirradiation of recurrent or second primary head and neck cancer[J].Int J Radiat Oncol Biol Phys,2018,100(3):595-605.
[44] SARI S Y,YILMAZ M T,AKTAS B Y,et al.Results of concurrent radiotherapy and immunotherapy in recurrent and metastatic head and neck cancer:a single-center experience[J].Oral Oncol,2022,124:105658.
[45] MCBRIDE S,SHERMAN E,TSAI C J,et al.Randomized phase ii trial of nivolumab with stereotactic body radiotherapy versus nivolumab alone in metastatic head and neck squamous cell carcinoma[J].J Clin Oncol,2021,39(1):30-37.
[46] PLAVC G,JESENKO T,ORAŽEM M,et al.Challenges in combining immunotherapy with radiotherapy in recurrent/metastatic head and neck cancer[J].Cancers(Basel),2020,12(11):3197.
[47] SEIWERT T Y,KIESS A P.Time to debunk an urban myth? The "abscopal effect" with radiation and anti-pd-1[J].J Clin Oncol,2021,39(1):1-3.
[48] MOLE R H.Whole body irradiation; Radiobiology or medicine?[J].Br J Radiol,1953,26(305):234-241.
[49] KALBASI A,JUNE C H,HAAS N,et al.Radiation and immunotherapy:a synergistic combination[J].J Clin Invest,2013,123(7):2756-2763.
[50] BUCHWALD Z S,WYNNE J,NASTI T H,et al.Radiation,immune checkpoint blockade and the abscopal effect:a critical review on timing,dose and fractionation[J].Front Oncol,2018,8:612.
[51] IONNA F,BOSSI P,GUIDA A,et al.Recurrent/metastatic squamous cell carcinoma of the head and neck:a big and intriguing challenge which may be resolved by integrated treatments combining locoregional and systemic therapies[J].Cancers(Basel),2021,13(10):2371. |
